Condition: Transthyretin Amyloidosis · Transthyretin Amyloid Cardiomyopathy · Wild-Type Transthyretin-Related (ATTR)Amyloidosis · Sponsor: Steen Hvitfeldt Poulsen
Descriptive cross-sectional study on 100 consecutive ATTRwt-CM patients reflecting all NAC stages aiming primarily to investigate ATTRwt-CM patient's quality of life (QoL) measures and their relation to ATTRwt-CM severity. Secondarily aiming to investigate the possibility to measure misTTR and fragTTR in plasma and urine and to detect fragTTR in endomyocardial biopsies from ATTRwt-CM patients. To investigate whether misTTR and fragTTR levels are correlated with ATTRwt-CM severity.
This description comes directly from the study's public registry record.
Sie Kronborg Fensman, MD · +45 30 48 88 85 · siefensman@gmail.com
Always discuss trial participation with your own doctor first.
| Aarhus University Hospital | Aarhus, Arrhus N, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06291805